Upstream Bio, Inc.
UPBHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframeUpstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. The $150.1M market capitalization puts UPB squarely in micro-cap range for its industry. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease.
Market Cap
$150.1M
Beta
1.39
P/E (TTM)
—
P/E (Fwd)
-0.98
EPS (TTM)
$-3.06
EPS (Fwd)
$-2.80
ROE
-46.1%
ROA
-30.3%
Cash
$261.3M
Total Debt
$954,000
Free CF
-$86.6M
52W Change
-88.4%
Annual Financials
Cash vs Debt
Where UPB stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, UPB finished 61.49% below its 150-day moving average ($7.27) and 73.21% below its 200-day moving average ($10.45). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is UPB overbought or oversold?
At the October 20, 2026 close, UPB's RSI(14) was 9.8, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $261.3M in cash and $954K in debt, UPB maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$86.6M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -46.1%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $1.2M (2022) to $2.9M (2025), reflecting a 135% increase over the period.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Upstream Bio, Inc.'s trajectory.